文献速递骨软组织肉瘤与黑色素瘤

糖皮质激素通过抑制GARP/TGFβ轴激活免疫依赖性黑色素瘤控制

Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis.
PubMed 文献 · Cancer Discov · 2026-01-01

在免疫治疗抵抗的小鼠黑色素瘤模型中,糖皮质激素(GCs)出人意料地引发细胞毒性T淋巴细胞(CTL)依赖的快速肿瘤控制。机制上,GCs直接作用于肿瘤细胞下调GARP表达,抑制TGFβ信号并释放CTL杀伤;高GC受体表达或信号的患者预后更好且肿瘤浸润CTL中TGFβ信号更低,GARP高表达与生存缩短相关。

要点

  • GCs通过肿瘤细胞内在的GARP下调抑制TGFβ信号,激活CTL依赖性抗肿瘤免疫。
  • GCs的疗效依赖于肿瘤对TGFβ信号抑制的响应性,在多种癌症模型中验证。
  • GARP高表达与黑色素瘤患者生存缩短相关,可能作为免疫治疗反应的生物标志物。

核心结论

  • GARP/TGFβ轴是GC敏感的肿瘤细胞内在免疫逃逸机制,GCs通过下调GARP抑制TGFβ信号并激活CTL依赖性肿瘤控制。

研究设计与样本

  • 在免疫治疗抵抗的小鼠黑色素瘤模型中测试局部药物抗癌活性,并通过遗传消融不同细胞区室的GC受体明确作用靶点。

主要发现

  • GCs在免疫治疗抵抗的小鼠黑色素瘤模型中引发快速CTL依赖性肿瘤控制。
  • GCs直接作用于肿瘤细胞下调GARP表达,抑制TGFβ信号并释放CTL杀伤。
  • GCs在多种癌症模型中刺激肿瘤控制,但仅当肿瘤也对TGFβ信号药理抑制有响应时。
  • 高GC受体表达或信号的黑色素瘤患者预后改善且肿瘤浸润CTL中TGFβ信号更低。
  • GARP表达升高与生存缩短相关,包括免疫治疗患者。

临床怎么用

  • GARP表达可能作为抗肿瘤免疫不良的生物标志物和改善免疫治疗响应的治疗靶点。
  • GCs的抗肿瘤作用依赖于肿瘤对TGFβ信号抑制的响应性,提示需评估TGFβ信号状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Half of patients with advanced melanoma fail to benefit from immune checkpoint blockade, and novel treatments are urgently required. Testing topical medications for anticancer activity in an immunotherapy-resistant murine melanoma model, we found that, counterintuitively, glucocorticoids (GCs) elicit rapid cytotoxic T lymphocyte (CTL)-dependent tumor control. Genetic ablation of the GC receptor in different cellular compartments revealed that GCs acted not on immune cells but directly on tumor cells to downregulate the expression of glycoprotein A repetitions predominant (GARP). This inhibited TGFβ signaling and unleashed CTL killing. In agreement, GCs stimulated tumor control in multiple cancer models but only if the tumors also responded to pharmacologic inhibition of TGFβ signaling. Furthermore, patients with melanoma with high GC receptor expression or signaling showed improved prognosis and lower TGFβ signaling in tumor-infiltrating CTLs. Additionally, elevated GARP expression correlated with reduced survival, including in immunotherapy-treated patients. Thus, the GARP/TGFβ axis emerges as a GC-sensitive cancer cell-intrinsic immune-evasive mechanism. SIGNIFICANCE: This study uncovers a surprising role for GCs in triggering CD8+ T cell-dependent tumor control through downregulation of GARP and thus TGFβ signaling. Analysis of samples from patients with melanoma suggested that GARP expression may serve as both a biomarker of poor antitumor immunity and a therapeutic target to improve the response to immunotherapy. See related commentary by Roest et al., p. 198.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Earnshaw CH, Dunn P, Chiang SC, et al. Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis. Cancer Discov. 2026. PMID: 41086837. doi:10.1158/2159-8290.CD-24-1224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。